The importance of MRD assessment in all phases of ALL treatment
Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Response to CAR T-cell treatment in CLL patients
Using reverse engineering to create biosimilars